Medical Therapeutics

Inapill

Brief Description

Inapill is developing novel therapeutics that tune immune cell metabolism (immunometabolism) to treat diseases caused by immune system overactivation and excessive inflammation.

Timeline 2023. Company founded; tenant at Bakar Labs, in the UC Berkeley Bakar BioEnginuity Hub Inventors

Kaoru Saijo, Greg Timblin

Lyterian Therapeutics, Inc.

Brief Description

Lyterian Therapeutics is committed to developing transformative medicines for patients by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically-validated targets. Lyterian is derived from λυτήριος or lutḗrios, which means termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. Lyterian Therapeutics medicines are inspired by the logic that orchestrates homeostatic equilibria and drives healing.

Timeline 2022....

Elenae Therapeutics

Brief Description

Applying antisense oligonucleotide technology to target coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

Timeline 2021. Company founded Inventors

Anders Naar, Sakari Kauppinen

DNA Nanobots, LLC

Brief Description

With a portfolio of existing IP, DNA Nanobots develops products for targeted therapeutics and functionalized gene delivery. We have a dual approach, building partnerships to provide development expertise in the functionalization of DNA nanotechnology with experience in Gene Delivery, Vaccine Development, Targeted Drug Delivery, Biosensing, Immunotherapy, and Drug Discovery.

Timeline 2021. Company founded. Inventors

Jennifer Doudna, Enrique Lin Shiao, Rachael Lew

Intellia

Brief Description

Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. Intellia leverages leading scientific expertise, clinical development experience, and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.

Timeline 2014. Company founded. Inventors

Jennifer Doudna, Emmanuelle Charpentier, James Doudna Cate, Krzysztof...

Magnetic Insight

Brief Description

Magnetic Insight is developing solutions in Magnetic Particle Imaging (MPI), a ground-breaking technology that will overcome major deficiencies with current clinical and translational research imaging techniques.

Magnetic Insight Inc. was founded by one of the leading research groups in the global field of Magnetic Particle Imaging from UC Berkeley. Developed over the past decade in the research lab of UC Berkeley Bioengineering and Electrical Engineering and Computer Science Professor Steven Conolly, MPI has proven in animal studies to generate high-contrast...

Catena Biosciences

Brief Description

Cantena Biosciences uncovered a novel protein conjugation method that can bring breakthroughs in biological therapeutics, autoimmune disorders, and vaccine development.

Catena’s technology allows the attachment of any two proteins together faster and more selectively than any competing method by attaching the natural amino acids tyrosine and cysteine. Since the company's platform uses only naturally occurring amino acids, it is more widely applicable than competing technologies and can be used to create complicated constructs far beyond...

Amber Bio

Brief Description

A biotechnology company offering genetic medicine through biologically inspired design. The company offers gene editing modalities using multi-kilobase RNA writing to easily reach previously undruggable diseases, enabling medical researchers to easily develop independent therapies for each separate mutation in the patient population.

Timeline 2021. Company founded Inventor

Jennifer Doudna

Mimesyn

Brief Description

Developing a novel class of molecules, aza-@-tides, that mimic the structural features of natural amino acids. These can be synthesized from amino acid precursors in either direction using standard peptide synthesis methods, facilitating the assembly of libraries incorporating all the amino acid building blocks.

Timeline 2004. Company founded Inventors

Paul Bartlett, Ming Chen Hammond, Stephen Olson, Scott Phillips, Miroslav Rezac

Vicinitas Therapeutics

Brief Description

Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs). The company’s mission is to use this proprietary technology to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins. The company spun out of technology that was developed through an academic-industry collaboration between UC Berkeley researchers and Novartis Institutes for BioMedical Research.

Timeline 2022...